HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

LY 341122

inibits lipid peroxidation

Also Known As:

2-(3,5-di-t-butyl-4-hydroxyphenyl)-4-(2-(4-methylethylaminomethylphenyloxy)ethyl)oxazole; LY341122

Networked: 2 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Oxazoles: 89
      - LY 341122: 2

Experts

1.	Belayev, L: 1 article (02/2000)
2.	Busto, R: 1 article (02/2000)
3.	Clemens, J A: 1 article (02/2000)
4.	Ginsberg, M D: 1 article (02/2000)
5.	Huh, P W: 1 article (02/2000)
6.	Panetta, J A: 1 article (02/2000)
7.	Zhao, W: 1 article (02/2000)

Related Diseases

1.	Brain Ischemia (Cerebral Ischemia) 02/11/2000 - "These results demonstrate the neuroprotective efficacy of LY341122 in focal cerebral ischemia." 02/11/2000 - "The purpose of this study was to examine the effect of LY341122 on ischemic injury in a highly reproducible model of focal cerebral ischemia in rats. "
2.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 02/11/2000 - "LY341122 significantly improved the neurological score compared to vehicle at 24, 48 and 72 h after middle cerebral artery occlusion. " 02/11/2000 - "The drug (LY341122, n=19) or vehicle (phosphate-buffered saline (PBS), n=10) was administered i.v. (as a 5 or 10 mg/kg bolus followed by a 5 or 10 mg/kg/h infusion for 20 h, respectively, starting 1 or 2 h after the onset of middle cerebral artery occlusion). "
3.	Contusions 09/01/1999 - "In the second experiment, rats treated with LY341122 at 5 minutes or 30 minutes after TBI also demonstrated a significant reduction (P < 0.05) in contusion volume (1.92 mm3 +/- 0.64 mm3 or 1.59 mm3 +/- 0.50 mm3, respectively) compared with vehicle-treated rats (4.32 mm3 +/- 1.15 mm3). " 09/01/1999 - "Oral administration of LY341122 before and after TBI led to a significant reduction in overall contusion volume (3.28 mm3+/-0.75 mm3 [mean +/- standard error of the mean] versus 1.32 mm3 +/- 0.33 mm3; P < 0.05) and also reduced the frequency of damaged cortical neurons (1191.7 +/- 267.1 versus 474.6 +/- 80.2; P < 0.05). "
4.	Ischemia 02/11/2000 - "LY341122 (2-(3, 5-di-t-butyl-4-hydroxyphenyl)-4-(2-(4-methylethylaminomethyl-ph enylox y)ethyl)oxazole) is a potent inhibitor of lipid peroxidation which has been shown to protect against global ischemia and traumatic brain injury in rats. "
5.	Infarction (Infarctions) 02/11/2000 - "Striatal infarct volume was also significantly reduced by treatment with LY341122 in the 10 mg/kg (1 h) group compared to vehicle (23.7+/-3.4 vs. 68. " 02/11/2000 - "Cortical infarct volume was significantly reduced by LY341122 treatment in the 10 mg/kg (1 h) and LY341122 10 mg/kg (2 h) groups compared to vehicle rats (14.7+/-9.5 vs. 106.8+/-20.9 mm(3), and 36.9+/-20.1 vs. 106. " 02/11/2000 - "Treatment with LY341122 significantly reduced total infarct volume in all treated groups compared to vehicle rats. "

Related Drugs and Biologics

1.	Phosphates (Orthophosphate)

Related Therapies and Procedures

1.	Oral Administration